Randomized Phase II, study to evaluate the efficacy of Paclitaxel in monotherapy vs Paclitaxel + Cetuximab (Erbitax) in patients with recurrent and/or metastatic head and neck squamous cell carcinoma that has progressed to extreme-type first line chemotherapy

Trial Profile

Randomized Phase II, study to evaluate the efficacy of Paclitaxel in monotherapy vs Paclitaxel + Cetuximab (Erbitax) in patients with recurrent and/or metastatic head and neck squamous cell carcinoma that has progressed to extreme-type first line chemotherapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2012

At a glance

  • Drugs Cetuximab (Primary) ; Paclitaxel
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Acronyms EXTAX
  • Most Recent Events

    • 20 Oct 2012 According to European Clinical Trails Database this study has been ended prematurely
    • 27 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top